• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    46 Biggest Movers From Yesterday

    12/16/21 4:42:57 AM ET
    $ABM
    $ADGI
    $ALZN
    $ASPU
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABM alert in real time by email

    Gainers

    • Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) gained 34.1% to settle at $12.58 on Wednesday.
    • CMC Materials, Inc. (NASDAQ:CCMP) climbed 33.9% to close at $195.50 on Wednesday after the company announced it will be acquired by Entegris for $6.5 billion in cash and stock.
    • Biofrontera Inc. (NASDAQ:BFRI) shares jumped 26.4% to settle at $6.95 on Wednesday after Benchmark initiated coverage on the stock with a Buy rating and announced a $11 price target.
    • Regional Health Properties, Inc. (NYSE:RHE) gained 23.8% to close at $6.70.
    • Regional Health Props, last month, posted a Q3 loss of $1.25 per share.
    • Gemini Therapeutics, Inc. (NASDAQ:GMTX) rose 23.1% to settle at $2.99 after HC Wainwright & Co initiated coverage on the stock with a Buy rating and a $20 price target.
    • CN Energy Group. Inc. (NASDAQ:CNEY) jumped 22.4% to close at $3.01.
    • Mesoblast Limited (NASDAQ:MESO) climbed 19.2% to settle at $4.97. Mesoblast shares dropped around 28% on Tuesday after the company was notified by Novartis that it has chosen to terminate the agreement with Mesoblast prior to closing.
    • Broadstone Acquisition Corp. (NYSE:BSN) gained 19.1% to close at $10.68.
    • Cabaletta Bio, Inc. (NASDAQ:CABA) jumped 18.2% to settle at $3.97.
    • Ensysce Biosciences, Inc. (NASDAQ:ENSC) surged 17.4% to close at $4.11. Ensysce Biosciences said that the first patients have been enrolled in Phase 1 study of PF614-MPAR, its unique technology platform to provide opioid overdose protection.
    • Trio-Tech International (NYSE:TRT) gained 16.6% to close at $9.42.
    • Aerovate Therapeutics, Inc. (NASDAQ:AVTE) jumped 16.3% to close at $12.34 after the company announced the initiation of its IMPAHCT Phase 2b/Phase 3 trial of AV-101 In Pulmonary Arterial Hypertension.
    • Optical Cable Corporation (NASDAQ:OCC) gained 16.2% to settle at $6.40.
    • Conn's, Inc. (NASDAQ:CONN) rose 16.1% to close at $20.81. Conn's Board of Directors authorized a repurchase program of $150 million of its outstanding stock.
    • Design Therapeutics, Inc. (NASDAQ:DSGN) surged 16% to settle at $20.36.
    • Bird Global, Inc. (NYSE:BRDS) gained 15.7% to close at $8.97.
    • VerifyMe, Inc. (NASDAQ:VRME) jumped 13.7% to close at $3.65.
    • East Stone Acquisition Corporation (NASDAQ:ESSC) gained 12.9% to close at $15.24 after declining 26% on Tuesday.
    • Vir Biotechnology, Inc. (NASDAQ:VIR) gained 12.1% to close at $51.62 after the company announced new preclinical data demonstrating the impact of the significant antigenic shift of the new SARS-CoV-2 Omicron variant.
    • SeaChange International, Inc. (NASDAQ:SEAC) rose 11.9% to close at $1.69 after the company reported better-than-expected Q3 results.
    • Nxt-ID, Inc. (NASDAQ:NXTD) shares rose 11.7% to close at $2.78 after the company said it was awarded U.S. General Services Administration contract to distribute personal emergency response systems to Federal, State and Local government purchasers.
    • Tandem Diabetes Care, Inc. (NASDAQ:TNDM) climbed 10.5% to close at $144.34.
    • Eli Lilly and Company (NYSE:LLY) climbed 10.4% to close at $275.28 after the company issued FY21 EPS guidance above analyst estimates.
    • Borr Drilling Limited (NYSE:BORR) gained 9.2% to close at $1.67 after declining over 4% on Tuesday..
    • Galera Therapeutics, Inc. (NASDAQ:GRTX) gained 7.4% to close at $2.90 after BTIG upgraded the stock from Neutral to Buy and announced a $15 price target. Galera Therapeutics shares jumped around 96% on Tuesday after the company announced the primary endpoint met statistical significance in corrected topline efficacy data of Phase 3 ROMAN trial of avasopasem.


    Check out these big penny stock gainers and losers

    Losers

    • Atai Life Sciences N.V. (NASDAQ:ATAI) dropped 31.9% to close at $6.82 on Wednesday.
    • China Xiangtai Food Co., Ltd. (NASDAQ:PLIN) fell 28.2% to settle at $1.81. The company earlier announced the completion of its first purchase of spot Bitcoin miners worth $7 million.
    • Aspen Group, Inc. (NASDAQ:ASPU) shares declined 27.2% to close at $1.90 on Wednesday after the company reported worse-than-expected Q2 results and cut FY22 guidance.
    • REV Group, Inc. (NYSE:REVG) fell 25.5% to close at $11.87 after the company reported worse-than-expected Q4 EPS and sales results and issued FY22 sales guidance below estimates.
    • Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) shares dipped 25.3% to close at $0.6501 on Wednesday after the company announced tilsotolimod updates. The company said no further enrollment in ILLUMINATE-206 trial is planned at this point.
    • LianBio (NASDAQ:LIAN) fell 21.3% to close at $7.68. LianBio reported a Q3 loss of $0.63 per share.
    • The Oncology Institute, Inc. (NASDAQ:TOI) fell 17.9% to close at $6.25.
    • Alzamend Neuro, Inc. (NASDAQ:ALZN) fell 15.9% to close at $2.59 after jumping 28% on Tuesday.
    • LogicBio Therapeutics, Inc (NASDAQ:LOGC) dropped 15.5% to close at $2.45. Barclays maintained LogicBio Therapeutics with an Overweight and lowered the price target from $24 to $8.
    • Legend Biotech Corporation (NASDAQ:LEGN) shares fell 15.3% to close at $41.14 after the company reported an offering of $300 million in ADSs.
    • Huadi International Group Co., Ltd. (NASDAQ:HUDI) fell 15% to close at $27.62.
    • iSpecimen Inc. (NASDAQ:ISPC) fell 13.3% to close at $10.87.
    • MIND Technology, Inc. (NASDAQ:MIND) shares fell 12.9% to close at $1.55. MIND Technology shares gained 30% on Tuesday after the company reported it entered into a Cooperative Research and Development Agreement with the United States Navy's Naval Surface Warfare Center, Panama City Division.
    • Adagio Therapeutics, Inc. (NASDAQ:ADGI) fell 12.5% to close at $6.35 after Stifel downgraded the stock from Buy to Hold and lowered the price target from $50 to $9. Adagio Therapeutics shares dipped 79% on Tuesday after the company said based on the in vitro findings related to Omicron, it plans to pause patient recruitment in its Phase 2/3 COVID-19 treatment trial at clinical sites in South Africa.
    • Zai Lab Limited (NASDAQ:ZLAB) fell 12.4% to close at $54.90.
    • Cerence Inc. (NASDAQ:CRNC) dropped 11.4% to close at $69.20. Cerence’s board promoted Dr. Stefan Ortmanns to Chief Executive Officer and Director.
    • ABM Industries Incorporated (NYSE:ABM) fell 11% to close at $40.88 as the company reported fourth-quarter revenue growth of 14.2% year-over-year to $1.69 billion, comprised of 7.4% organic growth and 6.8% from acquisition.
    • BeiGene, Ltd. (NASDAQ:BGNE) fell 10.7% to close at $248.56. BeiGene reported authorisation of BRUKINSA (zanubrutinib) from the UK’s MHRA for the treatment of adults with Waldenström’s Macroglobulinemia in Great Britain.
    • Cooper-Standard Holdings Inc. (NYSE:CPS) fell 7.1% to close at $19.71.
    • Nisun International Enterprise Development Group Co., Ltd (NASDAQ:NISN) fell 6.9% to close at $3.50.
    • I-Mab (NASDAQ:IMAB) fell 5% to close at $46.97. I-Mab received IND approval for Phase 1 clinical trial of bispecific antibody TJ-CD4B in solid tumors in China.
    Get the next $ABM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABM
    $ADGI
    $ALZN
    $ASPU

    CompanyDatePrice TargetRatingAnalyst
    Cerence Inc.
    $CRNC
    4/3/2026$11.00Overweight
    Cantor Fitzgerald
    Cerence Inc.
    $CRNC
    4/2/2026$11.00Overweight
    Cantor Fitzgerald
    AtaiBeckley Inc.
    $ATAI
    3/27/2026$12.00Buy
    Deutsche Bank
    Tandem Diabetes Care Inc.
    $TNDM
    3/19/2026$35.00Hold → Buy
    Truist
    Eli Lilly and Company
    $LLY
    3/17/2026$850.00Hold → Reduce
    HSBC Securities
    Tandem Diabetes Care Inc.
    $TNDM
    3/17/2026$33.00Neutral → Overweight
    Piper Sandler
    Design Therapeutics Inc.
    $DSGN
    3/16/2026$15.00Buy
    Jefferies
    ABM Industries Incorporated
    $ABM
    3/11/2026$50.00Hold → Buy
    Maxim Group
    More analyst ratings

    $ABM
    $ADGI
    $ALZN
    $ASPU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Trio-Tech International (TRT) Announces Pricing of $10 Million Registered Direct Offering

    Trio-Tech International ("Trio-Tech" or the "Company") (NYSE:TRT), a comprehensive provider of semiconductor back-end solutions and a global value-added supplier of electronic equipment, today announced that it has entered into securities purchase agreements with fundamental institutional investors for the purchase and sale of 1,052,632 shares of its common stock in a registered direct offering (the "Offering"). The closing of the Offering is expected to occur on or about April 27, 2026, subject to the satisfaction of customary closing conditions. D. Boral Capital LLC is acting as exclusive placement agent for the Offering. The gross proceeds to the Company from the Offering are expecte

    4/24/26 9:00:00 AM ET
    $TRT
    Industrial Machinery/Components
    Technology

    ABM Recognized with Edison Award for Commercial Technology Innovation

    NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- ABM (NYSE:ABM), a leading provider of facility, engineering, and infrastructure solutions, today announced it has been recognized with an Edison Award in the Commercial Technology category for its innovative ABM Connect data intelligence platform. ABM Connect was recognized for its ability to transform traditional facility operations into intelligent, data-driven ecosystems, unifying data from people, systems, and sensors to deliver real-time visibility, predictive insights, and measurable operational improvements. "Recognition from the Edison Awards further validates the measurable impact that ABM Connect is having on our clients," said Scott

    4/23/26 4:05:00 PM ET
    $ABM
    Diversified Commercial Services
    Consumer Discretionary

    Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

    Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate update and discuss its financial results for the first quarter ended March 31, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-mas

    4/23/26 4:05:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABM
    $ADGI
    $ALZN
    $ASPU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 28, 2025 - FDA Roundup: February 28, 2025

    For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

    2/28/25 5:00:47 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABM
    $ADGI
    $ALZN
    $ASPU
    SEC Filings

    View All

    SEC Form DEFA14A filed by Design Therapeutics Inc.

    DEFA14A - Design Therapeutics, Inc. (0001807120) (Filer)

    4/23/26 4:08:17 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Design Therapeutics Inc.

    DEF 14A - Design Therapeutics, Inc. (0001807120) (Filer)

    4/23/26 4:06:14 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by AtaiBeckley Inc.

    DEFA14A - AtaiBeckley Inc. (0002081043) (Filer)

    4/22/26 5:17:27 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABM
    $ADGI
    $ALZN
    $ASPU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Chernett Jorey bought $1,225,101 worth of shares (398,985 units at $3.07), increasing direct ownership by 4% to 10,251,929 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/17/26 7:40:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Director Bobbili Raja bought $585,059 worth of shares (71,000 units at $8.24) (SEC Form 4)

    4 - ContextLogic Holdings Inc. (0002064307) (Issuer)

    3/16/26 9:17:56 PM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    Director Mastrocola David John bought $208,144 worth of shares (6,885 units at $30.23) (SEC Form 4)

    4 - Cooper-Standard Holdings Inc. (0001320461) (Issuer)

    3/13/26 5:05:43 PM ET
    $CPS
    Auto Parts:O.E.M.
    Consumer Discretionary

    $ABM
    $ADGI
    $ALZN
    $ASPU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Administrative Officer England Kristin

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    4/23/26 9:25:46 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chief Clinical Officer Langsam Jeffrey

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    4/23/26 9:24:23 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Craig Kevin James

    4 - AtaiBeckley Inc. (0002081043) (Issuer)

    4/22/26 5:32:52 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABM
    $ADGI
    $ALZN
    $ASPU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Cerence with a new price target

    Cantor Fitzgerald initiated coverage of Cerence with a rating of Overweight and set a new price target of $11.00

    4/3/26 10:44:59 AM ET
    $CRNC
    Computer Software: Prepackaged Software
    Technology

    Cantor Fitzgerald initiated coverage on Cerence with a new price target

    Cantor Fitzgerald initiated coverage of Cerence with a rating of Overweight and set a new price target of $11.00

    4/2/26 8:09:15 AM ET
    $CRNC
    Computer Software: Prepackaged Software
    Technology

    Deutsche Bank initiated coverage on AtaiBeckley with a new price target

    Deutsche Bank initiated coverage of AtaiBeckley with a rating of Buy and set a new price target of $12.00

    3/27/26 8:46:10 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABM
    $ADGI
    $ALZN
    $ASPU
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Names Minh Merchant Chief Legal Officer

    CERRITOS, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Minh Merchant has joined the organization as Chief Legal Officer. In this role, Ms. Merchant will oversee legal, regulatory, compliance and privacy functions as TOI continues to scale. This role will be essential in enabling the company to continue its growth trajectory while further enhancing its mission to be a trusted healthcare partner to oncology patients and payors. Ms. Merchant has more than two decades of experience advising public and private healthcare organizations, including significant

    4/6/26 9:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    ContextLogic Appoints Paul S. Levy to Board of Directors

    OAKLAND, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- ContextLogic Holdings Inc. (OTCQB:LOGC) ("ContextLogic," the "Company," "we" or "our"), a business ownership platform focused on acquiring and building a portfolio of high-quality, long-duration businesses, today announced that its Board of Directors ("the Board") has appointed Paul S. Levy as an independent director. Mr. Levy was named a member of the Audit Committee. Similar to the directors affiliated with Abrams Capital and BC Partners, Mr. Levy will be waiving any compensation for his role as a director. Mr. Levy founded JLL Partners, a leading middle-market private equity firm, in 1988, where he has overseen investments across a w

    4/1/26 8:00:00 AM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary

    Aspen Group Announces Leadership Transition

    PHOENIX, March 16, 2026 (GLOBE NEWSWIRE) -- Aspen Group, Inc. ("AGI") (OTCQB:ASPU), an education technology holding company and the parent company of Aspen University (AU) and United States University (USU), announced today a leadership transition designed to support the company's next phase of growth and operational execution. Effective today, March 16, Matt LaVay, currently Chief Financial Officer of Aspen Group, will assume the role of Chief Executive Officer and will join the Aspen Group Board of Directors. Michael Mathews, who has served as Chief Executive Officer since 2012, will transition to Executive Chairman of the Board. The leadership transition is part of the company's planne

    3/16/26 8:00:00 AM ET
    $ASPU
    Other Consumer Services
    Consumer Discretionary

    $ABM
    $ADGI
    $ALZN
    $ASPU
    Financials

    Live finance-specific insights

    View All

    Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

    Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate update and discuss its financial results for the first quarter ended March 31, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-mas

    4/23/26 4:05:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026

    - Company to host conference call and webcast on May 7, 2026, at 8:00 a.m. ET (8:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its first quarter 2026 financial results and provide recent corporate updates on May 7, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). Conference Call and Webcast Information The live webcast can be accessed by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registration link for webcast (preferred): https://ed

    4/22/26 7:30:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABM
    $ADGI
    $ALZN
    $ASPU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

    SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)

    12/10/24 9:30:34 PM ET
    $BGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/6/24 4:05:57 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABM
    $ADGI
    $ALZN
    $ASPU
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Led to the Purchase at Aerovate Therapeutics Inc. on Jun 20?

    Recently, on June 20, 2024, a notable insider purchase was made at Aerovate Therapeutics Inc. Director Ra Capital Management, L.P. bought $1,549,944 worth of shares, acquiring 928,110 units at $1.67 per share as reported in the SEC Form 4. Insider transactions like these are closely watched by investors as they can provide valuable insights into the company's prospects. When analyzing insider transactions, it is essential to look for patterns and trends among multiple transactions to gauge the overall sentiment within the company. Several other SEC Form 4 filings were made around the same time, on June 7, 2024, by various insiders at Aerovate Therapeutics Inc. These included transactions by

    6/21/24 3:23:59 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care